Abstract
One of the most frequent epigenetic modifications of RNA in eukaryotes is N6 methyladenosine (m(6)A), which is mostly present in messenger RNAs. Through the influence of several RNA processing stages, m(6)A modification is a crucial approach for controlling gene expression, especially in cancer progression. It is universally acknowledged that numerous non-coding RNAs (ncRNAs), such as microRNAs, circular RNAs, long non-coding RNAs, and piRNAs, are also significantly affected by m(6)A modification, and the complex genetic regulatory relationship between m(6)A and ncRNAs plays a pivotal role in the development of cancer. The connection between m(6)A modifications and ncRNAs offers an opportunity to explore the oncogene potential regulatory mechanisms and suggests that m(6)A modifications and ncRNAs could be vital biomarkers for multiple cancers. In this review, we discuss the mechanisms of interaction between m(6)A methylation and ncRNAs in cancer, and we also summarize diagnostic and prognostic biomarkers for clinical cancer detection. Furthermore, our article includes some methodologies for identifying m(6)A sites when assessing biomarker potential.